Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

BACKGROUND: Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinum doublet. However, treatment for patients beyond the first line remains undefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Victoria E., Urisman, Anatoly, Albacker, Lee, Ali, Siraj, Miller, Vincent, Aggarwal, Rahul, Jablons, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604145/
https://www.ncbi.nlm.nih.gov/pubmed/28923100
http://dx.doi.org/10.1186/s40425-017-0281-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604145/
https://www.ncbi.nlm.nih.gov/pubmed/28923100
http://dx.doi.org/10.1186/s40425-017-0281-y

Ejemplares similares